<DOC>
	<DOCNO>NCT01992874</DOCNO>
	<brief_summary>This Phase 1 , multi-center , open-label , single-dose , 2 period , 2 sequence cross-over trial investigate relative bioavailability 2 solid oral pimasertib formulation cancer subject ( Part A ) , follow open-label pimasertib administration ( Part B trial extension phase ) .</brief_summary>
	<brief_title>Relative Bioavailability Pimasertib Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Pathologically confirm solid tumor , either refractory standard therapy effective standard therapy available , measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 An Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) less equal ( &lt; = ) 1 Other protocol define inclusion criterion could apply Disease condition concomitant medication may significantly influence conduct trial abnormal electrocardiogram ( ECG ) blood pressure Screening define protocol Treatment strong inhibitor inducer cytochrome P450 2C19 ( CYP2C19 ) CYP3A4 include fruit juice beverages contain substance History prior mitogenactivated protein kinase/extracellular signalregulated kinase ( MAPK/ERK ) kinase ( MEK ) inhibitor exposure ( include , pimasertib ) progression disease MEK inhibitor Evidence retinal vein occlusion ( RVO ) fluorescein angiogram history RVO Life expectancy le 12 week Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Pimasertib</keyword>
	<keyword>Cancer</keyword>
</DOC>